US Patent

US11802115 — Pharmaceutical formulation of odevixibat

Formulation · Assigned to Albireo AB · Expires 2039-06-20 · 13y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical formulation of odevixibat, which is a pediatric formulation comprising small particles, for treating liver diseases such as cholestatic liver diseases.

USPTO Abstract

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

Drugs covered by this patent

Patent Metadata

Patent number
US11802115
Jurisdiction
US
Classification
Formulation
Expires
2039-06-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.